Table 3. Gross estimates and adjusted risk of death for patients diagnosed with prostate cancer and treated between 2002–2003 in SUS, Brazil.
| Characteristics studied | Gross HR | Adjusted HR |
|---|---|---|
|
|
|
|
| (95%CI)a | (95%CI)a,b | |
| Age group at the start of the follow-up (years)c,d | ||
| 20–59 | 1.00 | 1.00 |
| 60–69 | 0.81 (0.73–0.90) | 0.85 (0.77–0.94) |
| 70–79 | 0.77 (0.69–0.85) | 0.82 (0.74–0.91) |
| ≥ 80 | 0.98 (0.88–1.11) | 0.96 (0.85–1.08) |
| Region of residencec | ||
| Southeast | 1.00 | 1.00 |
| South | 1.42 (1.30–1.54) | 1.12 (1.03–1.22) |
| Midwest | 1.26 (1.09–1.45) | 0.93 (0.80–1.07) |
| North | 1.00 (0.82–1.23) | 1.02 (0.83–1.25) |
| Northeast | 0.99 (0.92–1.08) | 0.99 (0.91–1.08) |
| Clinical stagesc,d | ||
| Stage I | 1.00 | 1.00 |
| Stage II | 1.20 (1.00–1.43) | 1.15 (0.96–1.37) |
| Stage III | 1.90 (1.59–2.26) | 1.66 (1.39–1.99) |
| Stage IV | 4.42 (3.73–5.23) | 3.49 (2.91–4.18) |
| First outpatient treatmentc,d | ||
| Radiotherapy | 1.00 | 1.00 |
| Hormone therapy – First line | 2.04 (1.89–2.20) | 1.28 (1.17–1.40) |
| Hormone therapy – Second line | 1.95 (1.78–2.15) | 1.39 (1.25–1.55) |
| Castration-resistant chemotherapy | 4.21 (3.21–5.52) | 2.34 (1.76–3.11) |
| Hospitalized in SUSc,d | ||
| No | 1.00 | 1.00 |
| Yes | 1.88 (1.76–2.01) | 1.67 (1.55–1.79) |
Source: Base Onco, 2006.
a HR = hazard ratio.
b Values adjusted by age group at the start of the follow-up, region of residence, clinical staging, first outpatient treatment and hospitalization in SUS.
c P-value in Grey’s test lower than 0.10 in the gross analysis.
d P-value in Grey’s test lower than 0.05 in the adjusted analysis.